Related references
Note: Only part of the references are listed.Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Perineural Mast Cells Are Specifically Enriched in Pancreatic Neuritis and Neuropathic Pain in Pancreatic Cancer and Chronic Pancreatitis
Ihsan Ekin Demir et al.
PLOS ONE (2013)
Immune infiltrates as predictive markers of survival in pancreatic cancer patients
Maria Pia Protti et al.
FRONTIERS IN PHYSIOLOGY (2013)
A Novel Survival-Based Tissue Microarray of Pancreatic Cancer Validates MUC1 and Mesothelin as Biomarkers
Jordan M. Winter et al.
PLOS ONE (2012)
Mast Cells in Tumor Microenvironment Promotes the In Vivo Growth of Pancreatic Ductal Adenocarcinoma
David Z. Chang et al.
CLINICAL CANCER RESEARCH (2011)
Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer
Emmanuel Mitry et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Masitinib Combined with Standard Gemcitabine Chemotherapy: In Vitro and In Vivo Studies in Human Pancreatic Tumour Cell Lines and Ectopic Mouse Model
Martine Humbert et al.
PLOS ONE (2010)
Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT
Patrice Dubreuil et al.
PLOS ONE (2009)
Meta-analysis of randomized trials: Evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer
Volker Heinemann et al.
BMC CANCER (2008)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Share Paper
